Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B16e2de94ee8255bd74cdd15da81f5743> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B16e2de94ee8255bd74cdd15da81f5743 NCIT_P378 "NCI" @default.
- B16e2de94ee8255bd74cdd15da81f5743 type Axiom @default.
- B16e2de94ee8255bd74cdd15da81f5743 annotatedProperty IAO_0000115 @default.
- B16e2de94ee8255bd74cdd15da81f5743 annotatedSource NCIT_C101789 @default.
- B16e2de94ee8255bd74cdd15da81f5743 annotatedTarget "Autologous dendritic cells tranduced with a replication incompetent adenovirus encoding human pro-inflammatory cytokine interleukin-12 (IL-12) (INXN-3001) in combination with the proprietary orally bioavailable, small molecule activator ligand INXN-1001, with potential immunomodulating and antineoplastic activities. Production of IL-12 is controlled by an inducible DNA element that allows transcription initiation only in the presence of the ligand inducer INXN-1001. Upon intratumoral injection of INXN-3001 and subsequent oral administration of activator ligand, INXN-1001 is able to induce expression of IL-12 in INXN-3001. IL-12 expressed by the adenovirus may activate the immune system by promoting the activation of natural killer cells, inducing the secretion of interferon-gamma and inducing a cytotoxic T lymphocyte response against tumor cells, which may result in immune-mediated tumor cell death and inhibition of tumor cell proliferation. As INXN-1001 regulates both the timing and the levels of IL-12 expression, IL-12 toxicity can be reduced." @default.